HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rapid response to sorafenib in metastatic medullary thyroid carcinoma.

AbstractOBJECTIVE:
To investigate the efficacy of sorafenib in progressive metastatic Medullary Thyroid Carcinoma (MTC), for which there is currently no effective treatment.
DESIGN:
Off-label observational study.
METHODS:
Sorafenib 400 mg twice daily was evaluated. The primary endpoint was the objective Response Evaluation Criteria in Solid Tumours (RECIST) score assessed on day 28 and every 12 weeks thereafter. Additional endpoints were time to response, duration of tumour response, tumour-related symptoms, and changes in tumour markers, calcitonin, and CEA measured initially, at 2 weeks, and then every 4 weeks. Therapy duration was 2 weeks, and 3-12 months.
RESULTS:
The 5 patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. 2 patients showed a partial response with tumour regression of -46% and -36% after 6 and 9 months, respectively, and 2 patients exhibited tumour regression of -14% and -29%, respectively (stable disease). Ultrasound-documented regression of -37% within 2 weeks occurred in 1 patient. Calcitonin decreased within 2 weeks in all patients by -69, -90, -75, -96, and -39%, respectively. 1 patient died because of progressive ascites from acute renal and hepatocellular failure. 2 patients developed grade 3 hand-foot syndrome within the first month, so that sorafenib was interrupted or reduced; other side effects were rash, fatigue, and hair loss. 3 patients remain on sorafenib, 2 at a reduced dosage (600 mg/d).
CONCLUSION:
These data suggest a possible role for sorafenib in the treatment of progressive metastatic MTC.
AuthorsK Frank-Raue, M Ganten, M C Kreissl, F Raue
JournalExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (Exp Clin Endocrinol Diabetes) Vol. 119 Issue 3 Pg. 151-5 (Mar 2011) ISSN: 1439-3646 [Electronic] Germany
PMID20827665 (Publication Type: Journal Article)
Copyright© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.
Chemical References
  • Antineoplastic Agents
  • Benzenesulfonates
  • Carcinoembryonic Antigen
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Calcitonin
  • sorafenib
Topics
  • Antineoplastic Agents (administration & dosage, adverse effects)
  • Benzenesulfonates (administration & dosage, adverse effects)
  • Calcitonin (blood)
  • Carcinoembryonic Antigen (blood)
  • Carcinoma, Neuroendocrine
  • Female
  • Humans
  • Male
  • Middle Aged
  • Niacinamide (analogs & derivatives)
  • Phenylurea Compounds
  • Pyridines (administration & dosage, adverse effects)
  • Thyroid Neoplasms (blood, drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: